JP2020504597A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504597A5
JP2020504597A5 JP2019520731A JP2019520731A JP2020504597A5 JP 2020504597 A5 JP2020504597 A5 JP 2020504597A5 JP 2019520731 A JP2019520731 A JP 2019520731A JP 2019520731 A JP2019520731 A JP 2019520731A JP 2020504597 A5 JP2020504597 A5 JP 2020504597A5
Authority
JP
Japan
Prior art keywords
composition
alcam
complex
monoclonal anti
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504597A (ja
JP7065085B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/056403 external-priority patent/WO2018073721A1/en
Publication of JP2020504597A publication Critical patent/JP2020504597A/ja
Publication of JP2020504597A5 publication Critical patent/JP2020504597A5/ja
Application granted granted Critical
Publication of JP7065085B2 publication Critical patent/JP7065085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520731A 2016-10-18 2017-10-16 Cd6のリン酸化を低減させるためのイトリズマブの使用 Expired - Fee Related JP7065085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641035602 2016-10-18
IN201641035602 2016-10-18
PCT/IB2017/056403 WO2018073721A1 (en) 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of cd6

Publications (3)

Publication Number Publication Date
JP2020504597A JP2020504597A (ja) 2020-02-13
JP2020504597A5 true JP2020504597A5 (cg-RX-API-DMAC10.html) 2020-11-26
JP7065085B2 JP7065085B2 (ja) 2022-05-11

Family

ID=62019244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520731A Expired - Fee Related JP7065085B2 (ja) 2016-10-18 2017-10-16 Cd6のリン酸化を低減させるためのイトリズマブの使用

Country Status (8)

Country Link
US (2) US20190248913A1 (cg-RX-API-DMAC10.html)
EP (1) EP3528846A4 (cg-RX-API-DMAC10.html)
JP (1) JP7065085B2 (cg-RX-API-DMAC10.html)
KR (1) KR102469798B1 (cg-RX-API-DMAC10.html)
AU (1) AU2017345390B2 (cg-RX-API-DMAC10.html)
CA (1) CA3076861A1 (cg-RX-API-DMAC10.html)
IL (1) IL266087B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018073721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
US20230076643A1 (en) * 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) * 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Similar Documents

Publication Publication Date Title
MX2022011935A (es) Terapeuticos de anticuerpo que se unen a ctla4.
WO2019126514A3 (en) Antibodies to lilrb2
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
HK1218550A1 (zh) 常見輕鏈小鼠
MX2017003565A (es) Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
HK1208994A1 (en) Methods for making fully human bispecific antibodies using a common light chain
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
EA201600354A1 (ru) Антигенсвязывающая молекула, содержащая вариабельную область антитела
BR112018015480A2 (pt) proteínas de ligação ao antígeno que se ligam a pd-l1
EP4545567A3 (en) Mice expressing a limited immunoglobulin light chain repertoire
PH12021550054A1 (en) Variants of cd38 antibody and uses thereof
WO2014055897A3 (en) Human monoclonal anti-pd-l1 antibodies and methods of use
PE20161092A1 (es) Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y uso de ellos
EA033072B1 (ru) Применение антител к семафорину 4d для лечения болезни хантингтона
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
WO2015161311A3 (en) Humanized anti-tf-antigen antibodies
JP2016183163A5 (cg-RX-API-DMAC10.html)
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
EP3768719A4 (en) HIGH AFFINITY NEUTRALIZING ANTIBODIES AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND THEIR USE
Ehrhold et al. Present-day sedimentation rates and evolution since the last maximum flooding surface event in the Bay of Brest (WN France)
Choi et al. SOME RECURRENCE RELATIONS FOR THE JACOBI POLYNOMIALS P (α, β) n (x)
HK40070609A (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
Cook Russia's Fragmented Welfare State
Roperch et al. Tectonic Evolution of the Patagonian Orocline: New Insights from a Paleomagnetic Study in Southernmost America